Trial Profile
An analysis of data from health insurance databases for patients with non-valvular atrial fibrillation treated with dabigatran etexilate or warfarin for prevention of stroke
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 14 Sep 2018
Price :
$35
*
At a glance
- Drugs Dabigatran etexilate (Primary) ; Warfarin
- Indications Stroke
- Focus Therapeutic Use
- 29 Aug 2018 Results presented at the ESC Congress 2018: Annual Congress of the European Society of Cardiology
- 24 Feb 2017 Results (n=21735)published in the Boehringer Ingelheim Pharmaceuticals media release.
- 11 Nov 2015 Interim results presented at the 88th Annual Scientific Sessions of the American Heart Association.